Abstract:To investigate the expression of vascular endothelial growth factor (VEGF)/VEGF-receptors and its relation to bone marrow angiogenesis in acute leukemia patients before and after chemotherapy.Bone marrow biopsies from 122 cases with different stages of human acute leukemia were immunostained with anti-vascular endothelial growth factor, anti-fms-like tyrosine kinase (Flt-1) and anti- kinase-domain insert containing receptor (KDR) antibodies with envision two-step immunohistochemical staining method.The expression of VEGF and KDR protein in remission patients was 5.3 (3.3 - 9.0) and 2.0 (1.0 - 4.0) being significantly lower than newly diagnosed untreated patients 6.0 (3.3 - 12.0) and 5.3 (3.3 - 8.0) (P < 0.05, 0.01). However nonsignificant decrease was shown among non-remission patients. In relapsed patients the expression of VEGF and KDR was significantly increased as compared with that in newly diagnosed patients. Flt-1 staining levels were in the same range between the newly diagnosed untreated patients and control group (P > 0.05), but significantly increased in remission or relapse patients, being 3.3 (1.7 - 5.3) in the remission group and 3.3 (2.0 - 5.3) in the relapse group (P < 0.01). Expression of VEGF and KDR protein was significantly higher in patients with a high degree of bone marrow microvessel counts as compared with those with a low degree and the expression correlated well with microvessel counts (P < 0.01). There was a positive correlation of the percentage of bone marrow blasts with VEGF and KDR expression in AML patients (r = 0.429, 0.359; P = 0.005, 0.02), and with VEGF expression in ALL patients (r = 0.522; P = 0.03).VEGF and its two specific cellular receptors are expressed in both haematopoietic cells and endothelial cells. VEGF may be a autocrine factor and modulates the angiogenic reaction in bone marrow as a paracrine factor. VEGF and its cellular receptor KDR may constitute promising targets for antiangiogenic and antileukemic treatment strategies.

[Study on Bone Marrow Microvascular Density in Hematological Diseases].

Study of Angiogenesis in Bone Marrow of Patients with Acute Leukemia

Levels of Bone Marrow Microvessel Density Are Crucial for Evaluating the Status of Acute Myeloid Leukemia.

Study on angiogenesis and vascular endothelial growth factor expression in plastic embedded bone marrow biopsy sections

Study on Bone Marrow Angiogenesis in Patients with Acute Leukemia

Significance of Microvessel Density in Bone Marrow of Patients with Aplastic Anemia

A Preliminary Observation of Bone Marrow Angiogenesis in Patients with Myelodysplastic Syndromes

Role of Bone Marrow Mobilization in the Angiogenesis in Ischemic Hindlimbs of Diabetic Mice

Impairment of bone marrow endothelial progenitor cells in acute graft-versus-host disease patients after allotransplant.

Increased Vascular Permeability in the Bone Marrow Microenvironment Contributes to Disease Progression and Drug Response in Acute Myeloid Leukemia

[Study on the Relationship Between Microvascular Density and Prognosis in Laryngeal Cancer].

[Change of Vascular Endothelial Growth Factor and Its Receptors Expression in Acute Myeloid Leukemia Before and after Treatment].

Measurement of Apoptosis and Tumor Necrosis Factor-Α(tnfα) in the Marrow of Patients with Mvelodvsplastic Svn Dromes

The Clinical Significance of Angiogenesis in Multiple Myeloma

Dynamic observation of vascular endothelial growth factor (VEGF)/VEGF-receptors expression in acute leukemia]

MICROVESSEL DENSITY AND EXPRESSION OF VEGFR-3 IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND ITS SIGNIFICANCE

Study on bone marrow angiogenic mediators and inhibitors in aplastic anemia

Relationship Between Adipocytes and Hematological Tumors in the Bone Marrow Microenvironment: a Literature Review

Observation of Bone Marrow Histology Pathology in MDS/MPD-CMML

Clinical Significance of the Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Expression in the Patients with Myelodysplastic Syndromes

Serum level of vascular endothelial growth factor in hematological malignancies